GIBSON DUNN

Gibson Dunn Advising Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings

Firm News | December 17, 2025

Gibson Dunn is advising Yarrow Bioscience on its merger with VYNE Therapeutics and concurrent $200 million financings.

Our corporate team includes partners Ryan Murr, Melanie Neary, and Branden Berns and associates Evan Shepherd and Candice Johnson.

Related People

Ryan A. Murr

Melanie E. Neary

Branden C. Berns

Evan Shepherd

Candice D. Johnson

Related Capabilities

Life Sciences

Mergers and Acquisitions

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**